| 陆莎 孙盈 陈召 王居正 王武平 张继朋 卢强.不同化疗方案联合手术治疗非小细胞肺癌的临床疗效及对患者免疫功能的影响分析[J].现代生物医学进展英文版,2016,16(30):5882-5885. |
| 不同化疗方案联合手术治疗非小细胞肺癌的临床疗效及对患者免疫功能的影响分析 |
| Analysis of Clinical Efficacy and Effect on the Immune Function of DifferentChemotherapy which combined with Surgery in the Treatment of Non SmallCell Lung Cancer Patients |
| |
| DOI： |
| 中文关键词: 非小细胞肺癌 化疗 手术 免疫功能 |
| 英文关键词: Non-small cell lung cancer Chemotherapy Surgery Immunity |
| 基金项目: |
|
| Hits: 896 |
| Download times: 0 |
| 中文摘要: |
| 目的：探讨分析不同化疗方案联合手术治疗非小细胞肺癌的临床疗效以及对患者免疫功能的影响。方法：经病理学证实的非
小细胞肺癌患者94 例，随机数字表法将其分为顺铂组与洛铂组，各47例。2 组患者均采取手术治疗，并术前行辅助化疗。其中顺
铂组采取紫杉醇+顺铂方案，洛铂组接受紫杉醇+洛铂方案。比较治疗前后2 组患者临床疗效及KPS评分，并对IgA、IgG、IgM、
CD4+及CD8+指标水平进行分析。结果：洛铂组有效率(CR+PR)为87.2%(41/47)，与顺铂组[80.8%(38/47)]差异无统计学意义(P>0.
05)。洛铂组术后KPS 评分及CD4+水平高于顺铂组(P<0.05)，但CD8+水平低于顺铂组(P<0.05)，差异有统计学意义；2组患者手术
前后IgA、IgG 及IgM均无统计学意义(P>0.05)。洛铂组毒副反应发生率低于顺铂组(P<0.05)。结论：含洛铂术前辅助化疗方案有助
于改善非小细胞肺癌患者的免疫功能，降低化疗的毒副反应。 |
| 英文摘要: |
| Objective:To investigate the clinical efficacy and immune function of different chemotherapy combined with surgery
in the treatment of patients with non-small cell lung cancer.Methods:94 cases of non-small cell lung cancer confirmed by pathology
were randomly divided into cisplatin group and lobaplatin group respectively, each of 47 cases. They all treated with surgery and
conducted to the supporting chemotherapy in the former. The cisplatin group received paclitaxel and cisplatin, while the lobaplatin group
received paclitaxel and lobaplatin. The total effective rate, KPS score, IgA, IgG, IgM, CD4+ and CD8+ between both groups were
compared.Results:The total effective rate was 87.2%(41/47) in the lobaplatin group and 80.8%(38/47) in the cisplatin group
respectively, there was no significant difference between both groups (P>0.05). The KPS score and CD4+ level of the lobaplatin group
were higher than that of the cisplatin group (P<0.05), but the level of CD8+ was lower than that of the cisplatin group (P<0.05). The
level of IgG, IgM and IgA were no statistical significant difference in 2 groups (P>0.05). The incidence of adverse reaction in the
lobaplatin group was lower than that of the cisplatin group (P<0.05).Conclusion:Preoperative adjuvant chemotherapy with platinum
containing chemotherapy can improve the immune function in patients with non small cell lung cancer, and reduce the side effects of
chemotherapy. |
|
View Full Text
View/Add Comment Download reader |
| Close |
